Emerging Companies

Podcast: Scientific American Worldview Report and Scorecard Preview, Part One

In this two part series, Scientific American’s Jeremy Abbate talks to editors Mike May and Yali Friedman about the Worldview Report and Scorecard, which will be released at the upcoming BIO International Convention in Boston at a Super Session on June 19.

Podcast: Scientific American Worldview Report and Scorecard Preview, Part Two

Phyllis Dillinger, Women in Bio

Phyllis discusses the importance of making connections in the industry to propel women into leadership roles, and plans for the upcoming BIO International Convention in Boston, Mass. On June 18-21.

Therapeutic Discovery Project Defending America's Competitiveness in Biotechnology

Capital formation challenges in the industry have forced many biotech companies to halt projects, lay off staff or shutdown all together. Our analysis shows that the industry is approximately one-quarter smaller than it was in 2008.

Therapeutic Discovery Project Helps Scientists Working To Cure Cancer

BIO believes that the level of support provided by the TDP simply cannot meet the needs of the growing biotech field. As evidence of the project's popularity suggests, Congress should consider extending or expanding the project in order to support American innovation and speed the development of life-saving cures.

Therapeutic Discovery Project Is Working to Create & Protect American Jobs

The biotech industry is a thriving sector employing 1.3 million Americans in high quality, high paying jobs.

Laura Shawver, PhD, CEO, Cleave Biosciences

Dr. Shawver discusses why this is an exciting time for the industry, and her experiences as a bench scientist turned CEO and founder of a patient advocacy group.

NIAMS Scientists: RA Drug Halts Organ Damage in Inflammatory Genetic Disorder

A new study shows that Kineret (anakinra), a medication approved for the treatment of rheumatoid arthritis, is effective in stopping the progression of organ damage in people with neonatal-onset multisystem inflammatory disease (NOMID).

Research Team Finds a New Breast Cancer Susceptibility Gene

Mutations in a gene called XRCC2 cause increased breast cancer risk, according to a study in the American Journal of Human Genetics.

Blockade of Learning and Memory Genes May Occur Early in Alzheimer's Disease

A repression of gene activity in the brain appears to be an early event affecting people with Alzheimer's disease, researchers funded by NIH have found.

NIH Study to Test Treatment for Fatty Liver Disease in Children

With the launch of a new clinical trial supported by NIH, researchers are working to determine whether treating children diagnosed with the most severe form of fatty liver disease with a drug called cysteamine will help improve the liver.

NHLBI Scientists: Gene Therapy Helps Patients with Hemophilia

A single dose of an experimental gene therapy boosted production of a missing blood-clotting factor in people with hemophilia, a new study shows.

NIAID Studies Show Benefits of Immediate Anti-retroviral Treatment for HIV-infected Infants

Results from studies presented March 6 at the Conference on Retroviruses & Opportunistic Infections in Seattle demonstrated the importance of identifying & treating HIV-infected infants within the first year of life to prevent harm to the immune system & to enable normal neurological development.

Developing Policies that Foster Innovation

Acorda Therapeutics' Ron Cohen presented testimony on the importance of federal policies to support the biotechnology industry at a House Committee on Science, Space and Technology, Subcommittee on Technology and Innovation hearing on March 27, a summary of his testimony is presented here

The JOBS Act: Critical Support for Today’s Emerging Biotech Company

The House and Senate passed H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act. It is now headed to the White House for President Obama’s signature.

Key Documents

The Economic Contribution of University/Nonprofit Inventions in the United States: 1996-2010

Bringing Innovation to Neglected Disease Research and Development: Joint Report by BIO and BIO Ventures for Global Health

Letters, Testimony & Comments

The 10th Anniversary of the Sarbanes-Oxley Act, Jeffrey S. Hatfield, President and Chief Executive Officer, Vitae Pharmaceuticals

July 26 2012

Jeffrey S. Hatfield, President and Chief Executive Officer of Vitae Pharmaceuticals, testified on behalf of BIO about the 10th anniversary of the Sarbanes-Oxley Act.

BIO Supports the JOBS Act (H.R. 3606)

March 16 2012

On behalf of BIO and its more than 1,100 members, Jim Greenwood submitted a letter to Senate Majority Leader Harry Reid and Minority Leader Mitch McConnell in strong support of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act.

Spurring Job Growth Through Capital Formation While Protecting Investors

March 6 2012

William D. Waddill, Senior Vice President and Chief Financial Officer of OncoMed Pharmaceuticals highlights the importance of capital formation to encourage investment in the biotechnology industry and spur job growth across the country.

BIO Written Testimony: Spurring Job Growth Through Capital Formation While Protecting Investors

December 1 2011

On December 1, BIO submitted written testimony to the Senate Committee on Banking, Housing, and Urban Affairs on the importance of implementing policies that will spur job growth through capital formation while protecting investors.

Driving Innovation and Job Growth Through the Life Sciences Industry

May 25 2011

Representatives of the bioscience industry testified before the U.S. Congress Joint Economic Committee today, as part of a hearing entitled Driving Innovation and Job Growth through the Life Sciences Industry.

More Letters, Testimony & Comments →